Affimed (AFMD) Competitors $1.15 +0.07 (+6.48%) As of 01/17/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends AFMD vs. UNCY, AVTX, VIGL, ANIX, CLSD, FBLG, GALT, CTMX, ZIVO, and VHAQShould you be buying Affimed stock or one of its competitors? The main competitors of Affimed include Unicycive Therapeutics (UNCY), Avalo Therapeutics (AVTX), Vigil Neuroscience (VIGL), Anixa Biosciences (ANIX), Clearside Biomedical (CLSD), FibroBiologics (FBLG), Galectin Therapeutics (GALT), CytomX Therapeutics (CTMX), ZIVO Bioscience (ZIVO), and Viveon Health Acquisition (VHAQ). These companies are all part of the "pharmaceutical products" industry. Affimed vs. Unicycive Therapeutics Avalo Therapeutics Vigil Neuroscience Anixa Biosciences Clearside Biomedical FibroBiologics Galectin Therapeutics CytomX Therapeutics ZIVO Bioscience Viveon Health Acquisition Unicycive Therapeutics (NASDAQ:UNCY) and Affimed (NASDAQ:AFMD) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their community ranking, valuation, dividends, institutional ownership, risk, media sentiment, profitability, analyst recommendations and earnings. Does the media refer more to UNCY or AFMD? In the previous week, Unicycive Therapeutics had 1 more articles in the media than Affimed. MarketBeat recorded 1 mentions for Unicycive Therapeutics and 0 mentions for Affimed. Unicycive Therapeutics' average media sentiment score of 1.95 beat Affimed's score of 1.00 indicating that Unicycive Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Unicycive Therapeutics Very Positive Affimed Positive Do analysts recommend UNCY or AFMD? Unicycive Therapeutics presently has a consensus price target of $5.50, suggesting a potential upside of 787.10%. Affimed has a consensus price target of $13.50, suggesting a potential upside of 1,073.91%. Given Affimed's higher possible upside, analysts clearly believe Affimed is more favorable than Unicycive Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Unicycive Therapeutics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.20Affimed 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.80 Which has preferable earnings & valuation, UNCY or AFMD? Unicycive Therapeutics has higher earnings, but lower revenue than Affimed. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioUnicycive Therapeutics$680K94.64-$30.54M-$0.97-0.64Affimed$8.95M2.07-$114.66MN/AN/A Do insiders and institutionals hold more shares of UNCY or AFMD? 40.4% of Unicycive Therapeutics shares are owned by institutional investors. Comparatively, 30.8% of Affimed shares are owned by institutional investors. 24.1% of Unicycive Therapeutics shares are owned by company insiders. Comparatively, 3.8% of Affimed shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Is UNCY or AFMD more profitable? Unicycive Therapeutics has a net margin of 0.00% compared to Affimed's net margin of -7,836.26%. Unicycive Therapeutics' return on equity of 0.00% beat Affimed's return on equity.Company Net Margins Return on Equity Return on Assets Unicycive TherapeuticsN/A N/A -29.88% Affimed -7,836.26%-193.84%-107.24% Which has more volatility and risk, UNCY or AFMD? Unicycive Therapeutics has a beta of 2.3, meaning that its share price is 130% more volatile than the S&P 500. Comparatively, Affimed has a beta of 2.17, meaning that its share price is 117% more volatile than the S&P 500. Does the MarketBeat Community favor UNCY or AFMD? Affimed received 408 more outperform votes than Unicycive Therapeutics when rated by MarketBeat users. However, 75.61% of users gave Unicycive Therapeutics an outperform vote while only 70.24% of users gave Affimed an outperform vote. CompanyUnderperformOutperformUnicycive TherapeuticsOutperform Votes3175.61% Underperform Votes1024.39% AffimedOutperform Votes43970.24% Underperform Votes18629.76% SummaryUnicycive Therapeutics beats Affimed on 13 of the 16 factors compared between the two stocks. Get Affimed News Delivered to You Automatically Sign up to receive the latest news and ratings for AFMD and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AFMD vs. The Competition Export to ExcelMetricAffimedPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$18.52M$6.21B$5.20B$9.14BDividend YieldN/A2.94%5.13%4.02%P/E RatioN/A9.2687.2517.09Price / Sales2.07309.921,263.9177.22Price / CashN/A61.4443.7736.04Price / Book0.276.055.314.79Net Income-$114.66M$154.90M$122.54M$224.99M7 Day Performance7.48%1.35%1.44%2.37%1 Month Performance-3.36%0.41%2.51%4.40%1 Year Performance-80.54%3.08%25.32%20.10% Affimed Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AFMDAffimed4.2898 of 5 stars$1.15+6.5%$13.50+1,073.9%-80.5%$18.52M$8.95M0.00200Positive NewsUNCYUnicycive Therapeutics3.4038 of 5 stars$0.69+3.4%$5.50+700.3%-28.4%$71.33M$680,000.00-0.719Positive NewsAVTXAvalo Therapeutics4.0397 of 5 stars$6.81-2.7%$40.00+487.4%+60.3%$70.78M$820,000.000.0040VIGLVigil Neuroscience3.9901 of 5 stars$1.73-3.6%$19.75+1,044.9%-32.5%$70.52MN/A-0.8440Gap UpANIXAnixa Biosciences3.359 of 5 stars$2.19-2.7%$8.50+288.1%-51.4%$70.47M$210,000.00-5.625Positive NewsCLSDClearside Biomedical3.2175 of 5 stars$0.93-5.6%$5.33+476.6%-27.9%$70.16M$7.70M-2.0630Positive NewsFBLGFibroBiologics1.915 of 5 stars$1.99+5.9%$13.00+553.3%N/A$69.82MN/A0.0010Gap UpGALTGalectin Therapeutics2.1349 of 5 stars$1.11+0.5%$11.00+895.5%-29.1%$69.35MN/A-1.519Positive NewsCTMXCytomX Therapeutics4.6352 of 5 stars$0.88+0.4%$5.77+553.5%-48.5%$69.13M$126.62M5.20170ZIVOZIVO BioscienceN/A$18.90-1.0%N/A+178.3%$68.44M$15,850.00-3.8710Gap UpVHAQViveon Health AcquisitionN/A$10.00flatN/AN/A$66.49MN/A0.002 Related Companies and Tools Related Companies UNCY Competitors AVTX Competitors VIGL Competitors ANIX Competitors CLSD Competitors FBLG Competitors GALT Competitors CTMX Competitors ZIVO Competitors VHAQ Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:AFMD) was last updated on 1/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredStunning Trump Exec Order LeakedThis secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode in 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe crypto bull market is here, and the stakes couldn’t be higher. The next 3-6 months? They’re the most ex...Crypto Swap Profits | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredElon’s New AI Firm REVEALEDNvidia’s AI chip … the H100 … has been the holy grail of artificial intelligence… Until now. Because Elo...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Affimed Please log in to your account or sign up in order to add this asset to your watchlist. Share Affimed With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
